Internal Medicine, Rheumatology · Covina, CA
NPI
1831104694
Since 2006
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
500 W San Bernardino Rd Ste A
Covina, CA, 91722
Phone (626) 966-1909
Groups this clinician bills Medicare through
Medicare paid, 2024
$3.0M
229,262 services
Medicare patients, 2024
1,072
Average age 73
Drug cost, 2024
$12.2M
13,050 prescriptions
Company payments, 2025
$250K
From 36 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Samy K Metyas was code J0717 (injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)), 58,454 times for 31 patients. In total Samy K Metyas billed 229,262 services in 123 codes, and Medicare paid $3.0M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2016-10-31.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| J0717 Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 58,454 | 31 | $3.61 | $211K |
| J1602 Injection, golimumab, 1 mg, for intravenous use | Office | 30,654 | 37 | $8.88 | $272K |
| J3111 Injection, romosozumab-aqqg, 1 mg | Office | 25,861 | 34 | $8.56 | $221K |
| J0897 Injection, denosumab, 1 mg | Office | 21,144 | 315 | $20.32 | $430K |
| J1010 Injection, methylprednisolone acetate, 1 mg | Office | 11,165 | 173 | $0.10 | $1,112 |
| 86235 Immunoassay | Office | 2,046 | 276 | $17.57 | $36K |
| 99214 Office E&M - Established | Office | 1,920 | 865 | $102.39 | $197K |
| J2919 Injection, methylprednisolone sodium succinate, 5 mg | Office | 1,752 | 33 | $0.23 | $395 |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 1,116 | 170 | $0.72 | $801 |
| J1745 Injection, infliximab, excludes biosimilar, 10 mg | Office | 1,027 | 16 | $23.95 | $25K |
| 86146 Immunoassay | Office | 876 | 276 | $24.94 | $22K |
| 86147 Immunoassay | Office | 876 | 276 | $24.94 | $22K |
| 96401 Chemotherapy Administration | Office | 799 | 72 | $68.36 | $55K |
| 96372 Injection Administration | Office | 769 | 401 | $12.55 | $9,654 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 727 | 520 | $13.32 | $9,686 |
By year: 2022 $2.6M for 162,608 services; 2023 $2.8M for 202,766 services; 2024 $3.0M for 229,262 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 86235 Immunoassay | 2,046 | 276 | $17.57 | $36K |
| 86146 Immunoassay | 876 | 276 | $24.94 | $22K |
| 86147 Immunoassay | 876 | 276 | $24.94 | $22K |
| 83516 Immunoassay | 630 | 295 | $11.30 | $7,119 |
| 82306 Clinical Chemistry | 324 | 290 | $29.01 | $9,399 |
| 86200 Immunoassay | 314 | 296 | $12.69 | $3,985 |
| 86431 Immunoassay | 314 | 296 | $5.56 | $1,746 |
| 86800 Immunoassay | 293 | 277 | $15.59 | $4,568 |
| 86376 Immunoassay | 293 | 277 | $14.26 | $4,178 |
| 86226 Immunoassay | 292 | 276 | $11.87 | $3,466 |
Medicare prescription drug claims, 2024
In 2024, the drug Samy K Metyas prescribed most often to Medicare patients was Prednisone, with 891 prescriptions and refills. In total Samy K Metyas wrote 13,050 Medicare prescriptions that cost $12.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Prednisone Generic | 891 | 1,310 | 216 | $4,112 |
| Methotrexate Methotrexate Sodium | 862 | 1,642 | 246 | $21K |
| Diclofenac Sodium Generic | 829 | 911 | 282 | $162K |
| Prolia Denosumab | 784 | 4,636 | 479 | $1.2M |
| Pregabalin Generic | 764 | 1,108 | 228 | $14K |
| Gabapentin Generic | 728 | 1,085 | 217 | $7,395 |
| Baclofen Generic | 715 | 1,070 | 231 | $6,821 |
| Hydroxychloroquine Sulfate Generic | 675 | 1,225 | 195 | $21K |
| Alendronate Sodium Generic | 590 | 1,338 | 210 | $4,226 |
| Duloxetine Hcl Generic | 484 | 843 | 140 | $9,697 |
| Meloxicam Generic | 381 | 409 | 112 | $757 |
| Celecoxib Generic | 255 | 351 | 64 | $5,822 |
| Tramadol Hcl Generic | 252 | 252 | 77 | $1,028 |
| Evenity (2 Syringes) Romosozumab-Aqqg | 247 | 247 | 56 | $590K |
| Folic Acid Generic | 221 | 496 | 81 | $1,184 |
Brand drugs: - claims; generic drugs: 10,205 claims; opioid claims: 426.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Samy K Metyas $250K ($230K in general payments such as food, travel and fees and $20K for research) from 36 companies. The largest payer was Amgen Inc. with $78K.
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. AMGN | 118 | $78K |
| Mallinckrodt Hospital Products Inc. | 36 | $35K |
| Abbvie Inc. ABBV | 50 | $31K |
| Lilly USA, LLC LLY | 25 | $23K |
| ANI Pharmaceuticals, Inc. ANIP | 29 | $19K |
| UCB, Inc. UCB.BR | 50 | $17K |
| Janssen Biotech, Inc. JNJ | 28 | $17K |
| Genzyme Corporation SNY | 11 | $12K |
| Kyowa Kirin, Inc. 4151.T | 12 | $7,097 |
| Novartis Pharmaceuticals Corporation NVS | 17 | $5,163 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.